One study highlights the use of tamoxifen (Tam)-loaded polymersomes, modified with the tumor-penetrating peptide iRGD, which targets fibronectin (FN)/β1 integrin interactions in estrogen receptor (ER)-positive breast cancer cell lines (MCF7, T47D, and HC11) [156]. This evidence concerns the gene ESR1 and breast carcinoma.